{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:10:47Z","timestamp":1791375047431,"version":"4.3.1"},"reference-count":17,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>COVID-19 and seasonal influenza vaccines were previously given separately, although their coadministration is warranted for vaccination adherence. Limited data on their coadministration have been published.<\/jats:p><\/jats:sec>Objective<\/jats:title>To compare the reactogenicity and immunogenicity of COVID-19 and influenza vaccinations administered together with those of COVID-19 vaccination alone.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This prospective cohort study included health care workers at a large tertiary medical center in Israel who received the Influvac Tetra (Abbott) influenza vaccine (2022\/2023), the Omicron BA.4\/BA.5\u2013adapted bivalent (Pfizer\/BioNTech) vaccine, or both. Vaccination began in September 2022, and data were collected until January 2023. Vaccines were offered to all employees and were coadministered or given separately. Adverse reaction questionnaires were sent, and serologic samples were also collected.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Receiving COVID-19 vaccine, influenza vaccine, or both.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The main outcomes for the reactogenicity analysis were symptoms following vaccine receipt, assessed by a digital questionnaire: any local symptoms; fever; weakness or fatigue; any systemic symptoms; and their duration. The immunogenicity analysis\u2019 outcome was postvaccination anti-spike IgG titer.<\/jats:p><\/jats:sec>Results<\/jats:title>This study included 2 cohorts for 2 separate analyses. The reactogenicity analysis included 588 participants (of 649 questionnaire responders): 85 in the COVID-19 vaccine\u2013alone group (median [IQR] age, 71 [58-74] years; 56 [66%] female); 357 in the influenza vaccine\u2013alone group (median [IQR] age, 55 [40-65] years; 282 [79%] female); and 146 in the coadministration group (median [IQR] age, 61 [50-71] years; 81 [55%] female). The immunogenicity analysis included 151 participants: 74 participants in the COVID-19 vaccine group (median [IQR] age, 67 [56-73] years; 45 [61%] female) and 77 participants in the coadministration group (median [IQR] age, 60 [49-73] years; 42 [55%] female). Compared with COVID-19 vaccination alone, the risk of systemic symptoms was similar in the coadministration group (odds ratio, 0.82; 95% CI, 0.43-1.56). Geometric mean titers in the coadministration group were estimated to be 0.84 (95% CI, 0.69-1.04) times lower than in the COVID-19 vaccine\u2013alone group.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of health care workers who received a COVID-19 vaccine, an influenza vaccine, or both, coadministration was not associated with substantially inferior immune response or to more frequent adverse events compared with COVID-19 vaccine administration alone, supporting the coadministration of these vaccines.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.32813","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T15:31:01Z","timestamp":1694187061000},"page":"e2332813","source":"Crossref","is-referenced-by-count":40,"title":["Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines"],"prefix":"10.1001","volume":"6","author":[{"given":"Tal","family":"Gonen","sequence":"first","affiliation":[{"name":"Sheba Pandemic Research Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel"},{"name":"The Infection Prevention & Control Unit, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Barda","sequence":"additional","affiliation":[{"name":"Sheba Pandemic Research Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel"},{"name":"ARC Innovation Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel"},{"name":"Software and Information Systems Engineering, Ben-Gurion University of the Negev, Be\u2019er Sheva, Israel"},{"name":"Epidemiology, Biostatistics and Community Health Services, Ben-Gurion University of the Negev, Be\u2019er Sheva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren","family":"Asraf","sequence":"additional","affiliation":[{"name":"The Dworman Automated-Mega Laboratory, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gili","family":"Joseph","sequence":"additional","affiliation":[{"name":"Sheba Pandemic Research Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel"},{"name":"The Infection Prevention & Control Unit, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Weiss-Ottolenghi","sequence":"additional","affiliation":[{"name":"Sheba Pandemic Research Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel"},{"name":"The Infection Prevention & Control Unit, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel"},{"name":"Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Doolman","sequence":"additional","affiliation":[{"name":"The Dworman Automated-Mega Laboratory, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel"},{"name":"Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitshak","family":"Kreiss","sequence":"additional","affiliation":[{"name":"Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel"},{"name":"General Management, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaniv","family":"Lustig","sequence":"additional","affiliation":[{"name":"Sheba Pandemic Research Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel"},{"name":"Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel"},{"name":"Central Virology Laboratory, Public Health Services, Ministry of Health, Tel-Hashomer, Ramat Gan, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gili","family":"Regev-Yochay","sequence":"additional","affiliation":[{"name":"Sheba Pandemic Research Institute, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel"},{"name":"The Infection Prevention & Control Unit, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel"},{"name":"Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"issue":"5","key":"zoi230950r1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.10650","article-title":"Evaluation of waning of SARS-CoV-2 vaccine-induced immunity: a systematic review and meta-analysis.","volume":"6","author":"Menegale","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"10318","key":"zoi230950r4","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1016\/S0140-6736(21)02329-1","article-title":"Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.","volume":"398","author":"Lazarus","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"zoi230950r5","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S2213-2600(21)00557-9","article-title":"Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged =65 years: a phase 2, randomised, open-label study.","volume":"10","author":"Izikson","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"2","key":"zoi230950r6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S2213-2600(21)00409-4","article-title":"Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial.","volume":"10","author":"Toback","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"36","key":"zoi230950r7","doi-asserted-by":"publisher","first-page":"5356","DOI":"10.1016\/j.vaccine.2022.07.021","article-title":"Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine (CoronaVac) co-administered with an inactivated quadrivalent influenza vaccine: a randomized, open-label, controlled study in healthy adults aged 18 to 59 years in China.","volume":"40","author":"Shenyu","year":"2022","journal-title":"Vaccine"},{"key":"zoi230950r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100628","article-title":"Timing and sequence of vaccination against COVID-19 and influenza (TACTIC): a single-blind, placebo-controlled randomized clinical trial.","volume":"29","author":"Dulfer","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"zoi230950r9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01390-2022","article-title":"Immunogenicity and safety of coadministration of COVID-19 and influenza vaccination.","volume":"61","author":"Wagenh\u00e4user","year":"2023","journal-title":"Eur Respir J"},{"issue":"24","key":"zoi230950r10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months.","volume":"385","author":"Levin","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi230950r11","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41590-022-01212-3","article-title":"Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose.","volume":"23","author":"Lustig","year":"2022","journal-title":"Nat Immunol"},{"issue":"429","key":"zoi230950r12","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1080\/01621459.1995.10476521","article-title":"Simultaneous confidence intervals and sample size determination for multinomial proportions.","volume":"90","author":"Sison","year":"1995","journal-title":"J Am Stat Assoc"},{"issue":"24","key":"zoi230950r13","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMp2211314","article-title":"A COVID-19 milestone attained\u2014a correlate of protection for vaccines.","volume":"387","author":"Gilbert","year":"2022","journal-title":"N Engl J Med"},{"key":"zoi230950r14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35480-2","article-title":"Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up.","author":"Canetti","year":"2022","journal-title":"Nature Communications"},{"issue":"5","key":"zoi230950r15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.14757","article-title":"Factors associated with protection from SARS-CoV-2 Omicron variant infection and disease among vaccinated health care workers in Israel.","volume":"6","author":"Gilboa","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"5","key":"zoi230950r16","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.cmi.2022.12.008","article-title":"Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workers.","volume":"29","author":"Radner","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"zoi230950r2","unstructured":"Australian Government Department of Health and Aged Care. Early advice on 2021 influenza vaccination. Accessed February 7, 2023. https:\/\/www.health.gov.au\/news\/early-advice-on-2021-influenza-vaccination"},{"key":"zoi230950r3","unstructured":"US Centers for Disease Control and Prevention. Getting a flu vaccine and a COVID-19 vaccine at the same time. Accessed February 7, 2023. https:\/\/www.cdc.gov\/flu\/prevent\/coadministration.htm"},{"key":"zoi230950r17","unstructured":"US Centers for Disease Control and Prevention. ACIP general best practice guidelines for immunization. Accessed March 20, 2023. https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/index.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2809119\/gonen_2023_oi_230950_1693333236.84305.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T15:31:06Z","timestamp":1694187066000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2809119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.32813","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,8]]}}}